Select Drug Profiles

Skip to main content

Payers' Guide, Select Drug Profiles

Tosymra (Sumatriptan) Nasal Spray Approved for the Acute Treatment of Migraine, with or without Aura

Select Drug Profiles, Payers' Guide

Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer

Select Drug Profiles, Payers' Guide

Udenyca (Pegfilgrastim-cbqv) Second Biosimilar Approved to Reduce the Incidence of Infection Associated with Febrile Neutropenia

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults

Lisa A. Raedler, PhD, RPh

Payers' Guide, Select Drug Profiles

Vitrakvi (Larotrectinib) First TRK Inhibitor Approved by the FDA for Solid Tumors Based on a Genetic Mutation

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Advanced Cutaneous Squamous-Cell Carcinoma

Select Drug Profiles, Payers' Guide

Xeljanz (Tofacitinib) Receives Expanded Indication, Becoming the First Oral JAK Inhibitor Approved for Ulcerative Colitis

Breast Cancer, FDA Approvals, In the News, Select Drug Profiles

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Breast Cancer, FDA Approvals, In the News, Select Drug Profiles

Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness

FDA Approvals, In the News, Lung Cancer, Select Drug Profiles

FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

6
7
8
9
10
11
12

Page 9 of 20
Results 81 - 90 of 200